(Q35104246)

6 August 2017

1 reference

title

Anti-angiogenic agents for the treatment of brain tumors (English)

1 reference

6 August 2017

angiogenesis inhibitor

1 reference

1 reference

Michael J Fisher

1

1 reference

PubMed ID

12687907

6 August 2017

Peter C Adamson

series ordinal

2

1 reference

6 August 2017

1 November 2002

1 reference

Neuroimaging clinics of North America

6 August 2017

1 reference

6 August 2017

12

1 reference

6 August 2017

4

1 reference

6 August 2017

477-499

1 reference

Tumor angiogenesis: therapeutic implications

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The implications of angiogenesis for the biology and therapy of cancer metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Angiogenesis and tumor metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

1 reference

7 January 2021

Models for assessment of angiogenesis in gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The vascular endothelial growth factor family of polypeptides

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Cardiovascular failure in mouse embryos deficient in VEGF receptor-3

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Mechanisms of angiogenesis in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor is a secreted angiogenic mitogen

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Genes that regulate metastasis and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

What, if anything, is an angiogenic factor?

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Tumor induction of VEGF promoter activity in stromal cells

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The role of vascular endothelial growth factor in pathological angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular permeability factor (VPF, VEGF) in tumor biology

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Purification and characterization of hypoxia-inducible factor 1

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Increased vascularization in mice overexpressing angiopoietin-1

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Anti-angiogenic treatment strategies for malignant brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The fibroblast growth factor family: structural and biological properties

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Human fibroblast-derived growth factor is a mitogen and chemoattractant for endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Basement membrane invasion of glioma cells mediated by integrin receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The urokinase-type plasminogen activator system in cancer metastasis: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Angiogenesis in malignant primary and metastatic brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Plasmin cleavage of vitronectin Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Inhibition of angiogenesis by tissue inhibitor of metalloproteinase

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Molecular mechanisms of tumor angiogenesis and tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Endostatin induces endothelial cell apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

A thrombin-sensitive protein of human platelet membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Downregulation of endothelial cell thrombospondin 1 enhances in vitro angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Secretion of matrix metalloproteinase-2 (72 kD gelatinase/type IV collagenase = gelatinase A) by malignant human glioma cell lines: implications for the growth and cellular invasion of the extracellular matrix.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Tumor Cell Invasion Inhibited by TIMP-2

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Tumor targeting with a selective gelatinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Grading of astrocytomas. A simple and reproducible method.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The new WHO classification of brain tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Microvessel density is a prognostic indicator for patients with astroglial brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Expression of vascular endothelial growth factor in human brain tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Fibroblast Growth Factor Messenger Ribonucleic Acid Expression in a Human Astrocytoma Cell Line: Regulation by Serum and Cell Density

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Assignment of the human endoglin gene (END) to 9q34-->qter

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Distribution of transforming growth factor-beta 1 in human astrocytomas

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Expression of vascular endothelial growth factor and its receptors in pilocytic astrocytoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Transforming growth factor beta 1-specific binding proteins on human vascular endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: evidence in support of an autocrine hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The effects of type beta transforming growth factor on proliferation and epidermal growth factor receptor expression in a human glioblastoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Expression of vascular endothelial growth factor in capillary hemangioblastoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptor flt-1 in microcystic meningiomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Expression and distribution of vascular endothelial growth factor protein in human brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Heterogeneous vascular dependence of tumor cell populations

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Suppression of tumor growth with recombinant murine angiostatin

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

TNP-470 (AGM-1470): mechanisms of action and early clinical development.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Anti-proliferative effects of TNP-470 on human malignant glioma in vivo: potent inhibition of tumor angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Suramin binds to platelet-derived growth factor and inhibits its biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Antiangiogenic and antiproliferative activity of suramin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Suramin is a Potent Inhibitor of Vascular Endothelial Growth Factor. A Contribution to the Molecular Basis of its Antiangiogenic Action

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Suramin inhibits C6 glioma-induced angiogenesis in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Suramin inhibits glioma cell proliferation in vitro and in the brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The efficacy and distribution of suramin in the treatment of the 9L gliosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase II trial of suramin in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Nature of interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(Carbonyl-bis[imino-N-methyl-4, 2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino] )bis-(1, 3-naphthalene disulfonate).

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Delayed vascular changes after antiangiogenic therapy with antivascular endothelial growth factor antibodies in human glioma xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Angiogenesis: regulators and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Antifibrinolytic therapy of experimentally grown malignant brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Preclinical and clinical studies of MMP inhibitors in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Marimastat in patients with advanced pancreatic cancer: a dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Marimastat (BB2516): current status of development

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

A phase II trial of marimastat in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Antiangiogenic strategies and agents in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The role of alphav integrins during angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

1 reference

7 January 2021

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Inhibitory effects of retinoids on vascular endothelial growth factor production by cultured human skin keratinocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin).

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

All-trans-retinoic acid: a phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Successful treatment of infantile hemangiomas with interferon-alpha-2b

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Immunobiology of primary intracranial tumors. Part 10: Therapeutic efficacy of interferon in the treatment of recurrent gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Clinical effect of interferon in malignant brain tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a childrens cancer group phase I/II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The effect of thalidomide on experimental tumors and metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Thalidomide as an anti-angiogenic agent in relapsed gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na+/H+ exchanger isoform NHE3.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Breast lesions: evaluation with dynamic contrast-enhanced T1-weighted MR imaging and with T2*-weighted first-pass perfusion MR imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging--parametric "first-pass" images depict tissue vascularization and perfusion.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Special techniques for imaging blood flow to tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Tumor angiogenesis and dynamic CT in lung adenocarcinoma: radiologic-pathologic correlation

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Development of angiogenesis inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Antiangiogenic therapy of transgenic mice impairs de novo tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Combined effects of angiostatin and ionizing radiation in antitumour therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Response of tumour cells to hypoxia: role of p53 and NFkB.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

p53, vessel count, and vascular endothelial growth factor expression in human colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Functions of the von Hippel-Lindau tumour suppressor protein

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Angiostatin binds ATP synthase on the surface of human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Inhibitory effect of full-length human endostatin on in vitro angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470.

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Studies with vascular smooth muscle cells and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Plasmin, fibrin degradation and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1052-5149%2802%2900035-7

7 January 2021

10.1016/S1052-5149(02)00035-7

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12687907